Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; citric acid monohydrate; pregelatinised maize starch; butylated hydroxyanisole; ascorbic acid; lactose monohydrate; purified talc; titanium dioxide; hypromellose; triacetin; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; ascorbic acid; microcrystalline cellulose; butylated hydroxyanisole; pregelatinised maize starch; purified talc; citric acid monohydrate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 8000; triacetin; iron oxide yellow; iron oxide red; polydextrose - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; ascorbic acid; magnesium stearate; purified talc; microcrystalline cellulose; citric acid monohydrate; pregelatinised maize starch; butylated hydroxyanisole; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 80 mg - tablet, film coated - excipient ingredients: purified talc; pregelatinised maize starch; magnesium stearate; lactose monohydrate; microcrystalline cellulose; citric acid monohydrate; butylated hydroxyanisole; ascorbic acid; titanium dioxide; hypromellose; triacetin; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 40 mg - tablet, film coated - excipient ingredients: citric acid monohydrate; pregelatinised maize starch; purified talc; microcrystalline cellulose; butylated hydroxyanisole; lactose monohydrate; magnesium stearate; ascorbic acid; titanium dioxide; hypromellose; macrogol 8000; triacetin; iron oxide yellow; iron oxide red; polydextrose - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 20 mg - tablet, film coated - excipient ingredients: ascorbic acid; citric acid monohydrate; butylated hydroxyanisole; purified talc; magnesium stearate; microcrystalline cellulose; lactose monohydrate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 10 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; purified talc; ascorbic acid; citric acid monohydrate; lactose monohydrate; magnesium stearate; butylated hydroxyanisole; titanium dioxide; hypromellose; triacetin; iron oxide red - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - simvastatin, quantity: 5 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose monohydrate; purified talc; ascorbic acid; microcrystalline cellulose; citric acid monohydrate; butylated hydroxyanisole; titanium dioxide; hypromellose; triacetin; iron oxide yellow - zimstat is indicated as an adjunct to diet for treatment of hypercholesterolaemia. prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated. zimstat is indicated in patients at high risk of coronary heart disease (chd) (with or without hypercholesterolaemia) including patients with diabetes, history of stroke or other cerebrovascular disease, peripheral vessel disease, or with existing chd to reduce the risk of cardiovascular death, major cardiovascular events including stroke, and hospitalisation due to angina pectoris. these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking. zimstat is indicated as an adjunct to diet in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heterozygous familial hypercholesterolaemia (hefh). prior to initiating therapy with zimstat, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Úc - Tiếng Anh - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc australasia pty ltd - azimsulfuron - water dispersible granule - azimsulfuron imidazolinones active 500.0 g/kg - herbicide - rice - see label - alisma | arrowhead | barnyard grass - suppression | dirty dora or variable flat sedge | spike rush | starfruit | water plantain - seedling | arrow head | common spike rush | common spike rush - suppressio | star fruit

Úc - Tiếng Anh - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc australasia pty ltd - azimsulfuron - unknown - azimsulfuron imidazolinones active 0.0 - active constituent